

Oregon Prescription Drug Price Transparency

Highlights from the 2021 Annual Report

January 11, 2022

Send written comments to rx.prices@dcbs.oregon.gov.



Drug Price Transparency Program

Program basics:


- Program operates under ORS 646A.680 to 646A.692 and administrative rules OAR 836-200-0500 to 836-200-0560

The program collects drug price information from these sources:

- Prescription drug manufacturers
- Insurance companies
- Consumers


Drug Price Transparency Program

Prescription drug supply chain



New high-cost drugs - 2021

Distribution of new high-cost drug reports by therapeutic class




New Drug Report - Aduhelm


- First new treatment approved for Alzheimer's in 20 years
- Approval was controversial:
 - Limited evidence of efficacy
 - Dangerous side effects
- Associated with 15% increase in Medicare Part B premiums
- May have an impact on OHP spending

2021 Price Increase Reports (data for 2020)

Program data – price increase reports 2019-2021





Marketwide – all net price increases 2011-2021




2021 Price Increase Reports (data for 2020)

Direct costs reported by prescription drug manufacturers



Data highlights from the 2021 annual report

Number of net price increases vs. average launch price of new drugs




2021 Insurer Reports (data for 2020)

- More prescriptions (761,044) were reported for antidepressants than for any other drug class.
- Humira – most prescribed specialty drug (19,225 prescriptions) and most costly (\$93,544,597).
- 3 drugs most responsible for increased plan spending:
 - Trikafta (Cystic Fibrosis) - \$15,826,660
 - Biktarvy (HIV) - \$10,114,820
 - Ultomiris (Blood diseases) - \$8,223,291

Data highlights from the 2021 annual report

Estimated expenditure on retail prescription drugs in U.S. (2005 to 2018)



Drug Price Transparency Program

Questions?

Program presenters:

- **Numi Lee Griffith**, Senior Policy Advisor, DFR
- **Jesse Ellis O'Brien**, Policy Section Manager, DFR

Program contact: rx.prices@dcbs.oregon.gov

Program info, including report, hearing: dfr.oregon.gov/drugtransparency